Literature DB >> 25394043

Factors associated with the continuum of care of HIV-infected patients in Belgium.

Dominique Van Beckhoven1, Patrick Lacor2, Michel Moutschen3, Denis Piérard4, André Sasse1, Dolorès Vaira5, Sigi Van den Wijngaert6, Bernard Vandercam7, Marc Van Ranst8, Eric Van Wijngaerden9, Linos Vandekerckhove10, Chris Verhofstede11, Ruth Verbrugge1, Rémy Demeester12, Stéphane De Wit13, Eric Florence14, Katrien Fransen15, Marie-Luce Delforge16, Jean-Christophe Goffard17, Patrick Goubau18.   

Abstract

INTRODUCTION: We studied factors associated with the continuum of HIV care in Belgium.
METHODS: Data of the national registration of new HIV diagnosis and of the national cohort of HIV-infected patients in care were combined to obtain estimates of and factors related with proportions of HIV-infected patients in each step of the continuum of care from diagnosis to suppressed viral load (VL). Factors associated with ignorance of HIV seropositivity were analyzed among patients co-infected with HIV and STI in the Belgian STI sentinel surveillance network. Associated factors were identified by multivariate logistic regression.
RESULTS: Among 4038 individuals diagnosed with HIV between 2007 and 2010, 90.3% were linked to care. Of 11684 patients in care in 2010, 90.8% were retained in care up to the following year, 88.3% of those were on ART, of whom 95.3% had suppressed VL (<500 cp/ml) (Figure 1). In multivariate analyses, factors associated with ignoring HIV+ status were being younger (p<0.001), being heterosexual compared to MSM, and of a region of origin other than Belgium, Sub-Saharan Africa and Europe. Non-Belgian regions of origin were associated with lower entry and retention in care (p<0.001 for both). Preoperative HIV testing was associated with lower entry in care (p=0.003). MSM had a higher retention in care (p<0.001), whilst IDU had lower retention (p=0.004). Low CD4 at first clinical contact and clinical reasons for HIV testing were independently associated with being on ART (p<0.001 for both); whilst prenatal HIV diagnosis was associated with lower proportion on ART (p=0.016) and lower proportion with suppressed VL among those on ART (p=0.005). Older age was associated with both being on ART and having suppressed VL among those on ART (p=0.007 and p<0.001 respectively), independently of time since HIV diagnosis (Table 1).
CONCLUSIONS: Regions of origin and risk groups (MSM/heterosexual/IDU) are the main factors associated with ignorance of HIV seropositivity, entry and retention in care, but once the HIV patient is retained in care, no effect of these factors on the proportions on ART and with suppressed VL are observed. The association of prenatal HIV diagnosis and proportions on ART and with suppressed VL could be biased by transitory CD4 disturbances during pregnancy and ART discontinuation after pregnancy. The higher probabilities of older patients to be on ART and have suppressed VL once retained in care could be influenced by factors not studied here like comorbidities, adherence or duration on ART.

Entities:  

Year:  2014        PMID: 25394043      PMCID: PMC4224910          DOI: 10.7448/IAS.17.4.19534

Source DB:  PubMed          Journal:  J Int AIDS Soc        ISSN: 1758-2652            Impact factor:   5.396


The continuum of HIV care in Belgium. Adjusted OR for factors associated with each step of the continuum of HIV care Note: Rem: p<0.05, statistically significant variables presented in italic. Adjusted for sex, age at diagnosis, nationality and ay of transmission additionally adjusted for CD4 value at first visit.
Table 1

Adjusted OR for factors associated with each step of the continuum of HIV care

Risk factorsAdjusted OR (95% CI)a Undiagnosed HIV +Adjusted OR (95% CI)a No entry in careAdjusted OR (95% CI)a No retentionAdjusted OR (95% CI)a On ARTAdjusted OR (95% CI)a Suppressed VL (<500 cp/ml)
Sex
Male11111
Female1.32 (0.39–4.44)0.88 (0.58–1.34)0.87 (0.70–1.07)0.76 (0.55–1.04)b 1.02 (0.73–1.42)
Age at diagnosis
<40 yrs11111
≥40 yrs0.42 (0.27–0.64)0.98 (0.69–1.39)1.05 (0.86–1.28)1.31 (1.04–1.65)b 1.75 (1.27–2.42)
Way of transmission
Heterosexual11111
MSM0.39 (0.16–0.95)0.86 (0.52–1.44)0.61 (0.47–0.78)0.80 (0.58–1.09)b 1.06 (0.72–1.56)
IDU/1.50 (0.55–4.11)1.88 (1.22–2.88)2.42 (0.69–8.46)b 1.46 (0.52–4.11)
Region of origin
Belgium11111
Sub-Saharan Africa1.02 (0.33–3.14)3.11 (1.84–5.26)1.41 (1.12–1.78)0.90 (0.66–1.23)b 0.73 (0.51–1.03)b
Europe0.83 (0.41–1.69)2.74 (1.59–4.71)1.86 (1.38–2.52)0.97 (0.67–1.40)b 0.97 (0.57–1.66)b
Other2.25 (1.26–4.04)3.23 (1.79–5.83)1.54 (1.10–2.17)0.90 (0.59–1.37)b 0.89 (0.51–1.48)
Reason for testing
Patient's request/1111
Clinical arguments/0.98 (0.64–1.50)0.95 (0.74–1.21)1.76 (1.34–2.31)b 0.92 (0.63–1.35)
Prenatal/1.14 (0.51–2.52)1.16 (0.75–1.78)0.49 (0.30–0.81)b 0.42 (0.23–0.78)
Preoperative/3.22 (1.50–6.89)1.21 (0.72–2.04)1.14 (0.56–2.31)b 0.85 (0.35–2.04)
Other/0.92 (0.55–1.54)1.13 (0.86–1.49)1.54 (1.11–2.14)b 1.03 (0.65–1.63)
CD4 at first visit
CD4 ≥350//111
CD4 <350//1.16 (0.89–1.51)8.02 (5.80–11.11)1.16 (0.78–1.70)

Note: Rem: p<0.05, statistically significant variables presented in italic.

Adjusted for sex, age at diagnosis, nationality and ay of transmission

additionally adjusted for CD4 value at first visit.

  7 in total

Review 1.  HIV treatment cascade in MSM, people who inject drugs, and sex workers.

Authors:  Kathryn Risher; Kenneth H Mayer; Chris Beyrer
Journal:  Curr Opin HIV AIDS       Date:  2015-11       Impact factor: 4.283

2.  Identifying, linking, and treating people who inject drugs and were recently infected with HIV in the context of a network-based intervention.

Authors:  Mina Psichogiou; George Giallouros; Katerina Pantavou; Eirini Pavlitina; Martha Papadopoulou; Leslie D Williams; Andria Hadjikou; Eleni Kakalou; Athanasios Skoutelis; Konstantinos Protopapas; Anastasia Antoniadou; George Boulmetis; Dimitrios Paraskevis; Angelos Hatzakis; Samuel R Friedman; Georgios K Nikolopoulos
Journal:  AIDS Care       Date:  2019-04-02

3.  Improving adoption and acceptability of digital health interventions for HIV disease management: a qualitative study.

Authors:  Kasey R Claborn; Ellen Meier; Mary Beth Miller; Eleanor L Leavens; Emma I Brett; Thad Leffingwell
Journal:  Transl Behav Med       Date:  2018-03-01       Impact factor: 3.046

4.  Clinic Network Collaboration and Patient Tracing to Maximize Retention in HIV Care.

Authors:  James H McMahon; Richard Moore; Beng Eu; Ban-Kiem Tee; Marcus Chen; Carol El-Hayek; Alan Street; Ian Woolley; Andrew Buggie; Danielle Collins; Nicholas Medland; Jennifer Hoy
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

5.  HIV continuum of care in Europe and Central Asia.

Authors:  R S Drew; B Rice; K Rüütel; V Delpech; K A Attawell; D K Hales; C Velasco; A J Amato-Gauci; A Pharris; L Tavoschi; T Noori
Journal:  HIV Med       Date:  2017-01-24       Impact factor: 3.180

6.  Assessing the HIV Care Continuum in Latin America: progress in clinical retention, cART use and viral suppression.

Authors:  Peter F Rebeiro; Carina Cesar; Bryan E Shepherd; Raquel B De Boni; Claudia P Cortés; Fernanda Rodriguez; Pablo Belaunzarán-Zamudio; Jean W Pape; Denis Padgett; Daniel Hoces; Catherine C McGowan; Pedro Cahn
Journal:  J Int AIDS Soc       Date:  2016-04-08       Impact factor: 5.396

7.  The HIV Care Continuum among Female Sex Workers: A Key Population in Lilongwe, Malawi.

Authors:  Kathryn Elizabeth Lancaster; Kimberly A Powers; Thandie Lungu; Pearson Mmodzi; Mina C Hosseinipour; Katy Chadwick; Vivian F Go; Brian W Pence; Irving F Hoffman; William C Miller
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.